Currently available biomaterials for use in cardiopulmonary bypass

Expert Review of Medical Devices

Volumn 3, Issue 3, 2006, Pages 345-355

  Belway, Dean ^a   Rubens, Fraser D ^a  

^a UNIVERSITY OF OTTAWA HEART INSTITUTE   (Canada)

Author keywords

Biocompatibility; Biomembrane mimicry; Cardiopulmonary bypass; heparin coated circuits; Inflammatory response; PMEA; SMA

Indexed keywords

ADEFOVIR; ANTIFIBRINOLYTIC AGENT; BIOMATERIAL; BRADYKININ; FIBRINOGEN; HEPARIN; IMMUNOGLOBULIN G; PHOSPHORYLCHOLINE; POLYMER; THROMBIN ANTITHROMBIN COMPLEX;

ANALYSIS OF VARIANCE; BIOCOMPATIBILITY; CARDIOPULMONARY BYPASS; CLINICAL PRACTICE; CLINICAL TRIAL; HUMAN; IN VITRO STUDY; KIDNEY DYSFUNCTION; LOW DRUG DOSE; LUNG DISEASE; NONHUMAN; PATHOPHYSIOLOGY; PREDICTION; REVIEW; THROMBOSIS; TREATMENT OUTCOME;

CARDIOPULMONARY BYPASS; COATED MATERIALS, BIOCOMPATIBLE; HUMANS; MATERIALS TESTING; SURFACE PROPERTIES; THROMBOSIS;

EID: 33646575590     PISSN: 17434440     EISSN: 17452422     Source Type: Journal    
DOI: 10.1586/17434440.3.3.345     Document Type: Review

References (93)

1. Wangensteen OH, Wangensteen SD. The Rise of Surgery. University of Minnesota Press, MN, USA (1978).
2. Walport MJ. Complement. First of two parts. N. Engl. J. Med. 344(14), 1058-1066 (2001).
3. Walport MJ. Complement. Second of two parts. N. Engl. J. Med. 344(15), 1140-1144 (2001).
4. Edmunds HL, Hessel EA, Colman RW, Menasche P. Extracorporeal circulation. In: Cardiac Surgery in the Adult. Edmunds HL, Cohn LH (Eds), McGraw-Hill Professional, NY, USA, 315-387 (2003).
5. Edmunds LH Jr. Advances in the heart-lung machine after John and Mary Gibbon. Ann. Thorac. Surg. 76(6), S2220-S2223 (2003).
6. Rubens FD. Cardiopulmonary bypass: technique and pathophysiology. In: Sabiston & Spencer Surgery of the Chest. Selke FW, del Nido PJ, Swanson SJ (Eds), Elsevier Saunders, PA, USA, 1061-1080 (2005).
7. Rubens FD. Cardiopulmonary bypass technology transfer: musings of a cardiac surgeon. J. Biomater. Sci. Polym. Ed. 13(4), 485-499 (2002).
8. Tanzi MC. Bioactive technologies for hemocompatibility. Expert Rev. Med. Devices 2(4), 473-492 (2005).
9. Campbell EJ, O'Byrne V, Stratford PW et al. Biocompatible surfaces using methacryloylphosphorylcholine laurylmethacrylate copolymer. ASAIO J. 40(3), M853-M857 (1994).
10. Mombouli JV, Vanhoutte PM. Endothelial dysfunction: from physiology to therapy. J. Mol. Cell. Cardiol. 31(1), 61-74 (1999).
11. Rubens FD, Labow RS, Lavallee GR et al. Hematologic evaluation of cardiopulmonary bypass circuits prepared with a novel block copolymer. Ann. Thorac. Surg. 67, 689-698 (1999).
12. Kitaguchi H, Hijikata A, Hirata M. Effect of thrombin on plasminogen activator release from isolated perfused dog leg. Thromb. Res. 16, 407-415 (1979).
13. Coughlin SR, Vu TK, Hung DT, Wheaton VI. Characterization of a functional thrombin receptor. Issues and opportunities. J. Clin. Invest. 89(2), 351-355 (1992).
14. Steinberg JB, Kapelanski DP, Olson JD, Weiler JM. Cytokine and complement levels in patients undergoing cardiopulmonary bypass. J. Thorac. Cardiovasc. Surg. 106(6), 1008-1016 (1993).
15. Cavarocchi NC, Pluth JR, Schaff HV et al. Complement activation during cardiopulmonary bypass. Comparison of bubble and membrane oxygenators. J. Thorac. Cardiovasc. Surg. 91(2), 252-258 (1986).
16. Wiggins RC, Giclas PC, Henson PM. Chemotactic activity generated from the fifth component of complement by plasma kallikrein of the rabbit. J. Exp. Med. 153(6), 1391-1404 (1981).
17. Ward PA. A plasmin-split fragment of C'3 as a new chemotactic factor. J. Exp. Med. 126(2), 189-206 (1967).
18. Tengvall P, Askendal A, Lundstrom I. Temporal studies on the deposition of complement on human colostrum IgA and serum IgG immobilized on methylated silicon. J. Biomed. Mater. Res. 35(1), 81-92 (1997).
19. Gorbet MB, Sefton MV. Biomaterial-associated thrombosis: roles of coagulation factors, complement, platelets and leukocytes. Biomaterials 25, 5681-5703 (2004).
20. Gott VL. And it happened during our lifetime. Ann. Thorac. Surg. 55(5), 1057-1064 (1993).
21. Voorhees ME, Brian BF. Blood-gas exchange devices. Int. Anesthesiol. Clin. 34(2), 29-45 (1996).
22. Rosen JJ. The role of biomaterials science in the next generation of artificial organ technology. ASAIO Thins. 34(3), 163-167 (1988).
23. Wendel HP, Ziemer G. Coating-techniques to improve the hemocompatibility of artificial devices used for extracorporeal circulation. Eur. J. Cardiothorac. Surg. 16(3), 342-350 (1999).
24. Gott VL, Daggett RL. Serendipity and the development of heparin and carbon surfaces. Ann. Thorac. Surg. 68, S19-S22 (1999).
25. Gott VL, Whiffen JD, Dutton RC. Heparin bonding on colloidal graphite surfaces. Science 14, 1297-1298 (1963).
26. Baier RE. The role of surface energy in thrombogenesis. Bull. N Y Acad. Med. 48(2), 257-272 (1972).
27. Lee JH, Lee HB. Platelet adhesion onto wettability gradient surfaces in the absence and presence of plasma proteins. J. Biomed. Mater. Res. 41(2), 304-311 (1998).
28. Salzman EW. Nonthrombogenic surfaces: critical review. Blood 38(4), 509-523 (1971).
29. Uniyal S, Brash JL. Patterns of adsorption of proteins from human plasma onto foreign surfaces. Thromb. Haemost. 47, 285-295 (1982).
30. Horbett TA. Proteins; structure, properties, and adsorption to surfaces. In: Biomaterials Science. An Introduction to Materials in Medicine. Ratner BD, Hoffman AS, Schoen FJ, Lemon JE (Eds), Academic Press, CA, USA, 133-141 (1996).
31. Brash JL, Scott CF, ten Hove P, Wojciechowski P, Colman RW. Mechanism of transient adsorption of fibrinogen from plasma to solid surfaces: role of the contact and fibrinolytic systems. Blood 71, 932-939 (1988).
32. Lindon JN, McManama G, Kushner L, Merrill EW, Salzman EW. Does the conformation of adsorbed fibrinogen dictate platelet interactions with artificial surfaces? Blood 68(2), 355-362 (1986).
33. Larm O, Larsson R, Olsson P. A new non-thrombogenic surface prepared by selective covalent binding of heparin via a modified reducing terminal residue. Biomater. Med. Devices Artif. Organs 11(2-3), 161-173 (1983).
34. Johnell M, Elgue G, Larsson R, Larsson A, Thelin S, Siegbahn A. Coagulation, fibrinolysis, and cell activation in patients and shed mediastinal blood during coronary artery bypass grafting with a new heparin-coated surface. J. Thorac. Cardiovasc. Surg. 124(2), 321-332 (2002).
35. Johnell M, Larsson R, Siegbahn A. The influence of different heparin surface concentrations and antithrombin-binding capacity on inflammation and coagulation. Biomaterials 26(14), 1731-1739 (2005).
36. Feyrer R, Harig F, Cesnjevar R. Bioline or Safeline treatment of CPB circuits? Cardiovasc. Eng. 8, 1-2 (2003).
37. Tayama E, Hayashida N, Akasu K et al. Biocompatibility of heparin-coated extracorporeal bypass circuits: new heparin bonded bioline system. Artif. Organs 24(8), 618-623 (2000).
38. Larson DF, Arzouman D, Kleinert L, Patula V, Williams S. Comparison of Sarns 3M heparin bonded to Duraflo II and control circuits in a porcine model: macro- and microanalysis of thrombi accumulation in circuit arterial filters. Perfusion 15(1), 13-20 (2000).
39. Rubens FD, Mesana T. The inflammatory response to cardiopulmonary bypass: a therapeutic overview. Perfusion 19(Suppl. 1), S5-S12 (2004).
40. Elgue G, Blomback M, Olsson P, Riesenfeld J. On the mechanism of coagulation inhibition on surfaces with end point immobilized heparin. Thromb. Haemost. 70(2), 289-293 (1993).
41. Ovrum E, Holen EA, Tangen G et al. Completely heparinized cardiopulmonary bypass and reduced systemic heparin: clinical and hemostatic effects. Ann. Thorac. Surg. 60(2), 365-371 (1995).
42. Aldea GS, Doursounian M, O'Gara P et al. Heparin-bonded circuits with a reduced anticoagulation protocol in primary CABG: a prospective, randomized study. Ann. Thorac. Surg. 62, 410-418 (1996).
43. Brown C. Heparin-bonded circuits: clinical outcomes and costs. Perfusion 13, 192-204 (1988).
44. Moen O, Høgasen K, Fosse E et al. Attenuation of changes in leukocyte surface markers and complement activation with heparin-coated cardiopulmonary bypass. Ann. Thorac. Surg. 63, 105-111 (1997).
45. Steinberg BM, Grossi EA, Schwartz DS et al. Heparin bonding of bypass circuits reduces cytokine release during cardiopulmonary bypass. Ann. Thorac. Surg. 60(3), 525-529 (1995).
46. Barstad RM, Ovrum E, Ringdal M-AL et al. Induction of monocyte tissue factor procoagulant activity during coronary artery bypass surgery is reduced with heparin-coated extracorporeal circuit. Br. J. Haematol. 94, 517-525 (1996).
47. Khuri S, Valeri CR, Loscalzo J et al. Heparin causes platelet dysfunction and induces fibrinolysis before cardiopulmonary bypass. Ann. Thorac. Surg. 60, 1008-1014 (1995).
48. Muriithi EW, Belcher PR, Day SP, Menys VC, Wheatley DJ. Heparin-induced platelet dysfunction and cardiopulmonary bypass. Ann. Thorac. Surg. 69(6), 1827-1832 (2000).
49. Morel DR, Zapol WM, Thomas SJ et al. C5a and thromboxane generation associated with pulmonary vaso- and broncho-constriction during protamine reversal of heparin. Anesthesiology 66(5), 597-604 (1987).
50. Wildevuur CR, Jansen PG, Bezemer PD et al. Clinical evaluation of Duraflo II heparin treated extracorporeal circulation circuits (2nd version). The European Working Group on heparin coated extracorporeal circulation circuits. Eur. J. Cardiothorac. Surg. 11(4), 616-623 (1997).
51. Ranucci M, Mazzucco A, Pessotto R et al. Heparin-coated circuits for high-risk patients: a multicenter, prospective, randomized trial. Ann. Thorac. Surg. 67, 994-1000 (1999).
52. Gorman RC, Ziats NP, Rao AK et al. Surface-bound heparin fails to reduce thrombin formation during clinical cardiopulmonary bypass. J. Thorac. Cardiovasc. Surg. 111, 1-12 (1996).
53. Edmunds LH. Surface-bound heparin - panacea or peril? Ann. Thorac. Surg. 58, 285-286 (1994).
54. Baufreton C, Jansen PG, Le Besnerais P et al. Heparin coating with aprotinin reduces blood activation during coronary artery operations. Ann. Thorac. Surg. 63(1), 50-56 (1997).
55. Videm V, Mollnes TE, Fosse E et al. Heparin-coated cardiopulmonary bypass equipment. I. Biocompatibility markers and development of complications in a high-risk population. J. Thorac. Cardiovasc. Surg. 117(4), 794-802 (1999).
56. Videm V, Mollnes TE, Bergh K et al. Heparin-coated cardiopulmonary bypass equipment. II. Mechanisms for reduced complement activation in vivo. J. Thorac. Cardiovasc. Surg. 117(4), 803-809 (1999).
57. Pekna M, Hagman L, Halden E, Nilsson UR, Nilsson B, Thelin S. Complement activation during cardiopulmonary bypass: effects of immobilized heparin. Ann. Thorac. Surg. 58, 421-424 (1994).
58. de Vroege R, Huybregts R, van Oeveren W et al. The impact of heparin-coated circuits on hemodynamics during and after cardiopulmonary bypass. Artif. Organs 29(6), 490-497 (2005).
59. Wendel HP, Weber N, Ziemer G. Increased adsorption of high molecular weight kininogen to heparin-coated artificial surfaces and correlation to hemocompatibility. Immunopharmacology 43(2-3), 149-153 (1999).
60. Olson ST, Sheffer R, Francis AM. High molecular weight kininogen potentiates the heparin-accelerated inhibition of plasma kallikrein by antithrombin: role for antithrombin in the regulation of kallikrein. Biochemistry 32(45), 12136-12147 (1993).
61. te Velthuis H, Baufreton C, Jansen PGM et al. Heparin coating of extracorporeal circuits inhibits contact activation during cardiac operations. J. Thorac. Cardiovasc. Surg. 114, 117-122 (1997).
62. Kazatchkine MD, Fearon DT, Silbert JE, Austen KF. Surface-associated heparin inhibits zymosan-induced activation of the human alternative complement pathway by augmenting the regulatory action of the control proteins on particle-bound C3b. J. Exp. Med. 150(5), 1202-1215 (1979).
63. Mollnes TE, Riesenfeld J, Garred P et al. A new model for evaluation of biocompatibility: combined determination of neoepitopes in blood and on artificial surfaces demonstrates reduced complement activation by immobilization of heparin. Artif. Organs 19(9), 909-917 (1995).
64. Deppisch R, Gohl H, Smeby L. Microdomain structure of polymeric surfaces - potential for improving blood treatment procedures. Nephrol. Dial. Transplant. 13(6), 1354-1359 (1998).
65. Tsai C-C, Deppisch RM, Forrestal LJ et al. Surface modifying additives for improved device-blood compatibility. ASAIO J. 40, M619-M624 (1994).
66. Lovinger AJ, Han BJ, Padden FJ, Mirau PA. Morphology and properties of polycaprolactone-poly(dimethyl siloxane)- polycaprolactone triblock copolymers. J. Polymer Sci. 31, 115-123 (1993).
67. Okano T, Nishiyama S, Shinohara I et al. Effect of hydrophilic and hydrophobic microdomains on mode of interaction between block polymer and blood platelets. J. Biomed. Mater. Res. 15(3), 393-402 (1981).
68. Okano T, Aoyagi T, Kataoka K et al. Hydrophilic-hydrophobic microdomain surfaces having an ability to suppress platelet aggregation and their in vitro anti-thrombogenicity. J. Biomed. Mater. Res. 20, 919-927 (1986).
69. Defraigne JO, Pincemail J, Dekoster G et al. SMA circuits reduce platelet consumption and platelet factor release during cardiac surgery. Ann. Thorac. Surg. 70(6), 2075-2081 (2000).
70. Allen S, McBride WT Young IS et al. A clinical, renal and immunological assessment of surface modifying additive treated (SMART) cardiopulmonary bypass circuits. Perfusion 20(5), 255-262 (2005).
71. Suhara H, Sawa Y, Nishimura M et al. Efficacy of a new coating material, PMEA, for cardiopulmonary bypass circuits in a porcine model. Ann. Thorac. Surg. 71(5), 1603-1608 (2001).
72. Saito N, Motoyama S, Sawamoto J. Effects of new polymer-coated extracorporeal circuits on biocompatibility during cardiopulmonary bypass. Artif. Organs 24(7), 547-554 (2000).
73. Ueyama K, Nishimura K, Nishina T, Nakamura T, Ikeda T, Komeda M. PMEA coating of pump circuit and oxygenator may attenuate the early systemic inflammatory response in cardiopulmonary bypass surgery. ASAIO J. 50(4), 369-372 (2004).
74. Izuha H, Hattori M, Igari T, Wakamatsu D, Watanabe M, Yokoyama H. Changes in platelet aggregation during cardiopulmonary bypass: comparison of poly-2-methoxyethylacrylate and heparin as a circuit coating material. J. Artif. Organs 8(1), 41-46 (2005).
75. Gemmell CH, Ramirez SM, Yeo EL, Sefton MV. Platelet activation in whole blood by artificial surfaces: identification of platelet-derived microparticles and activated platelet binding to leukocytes as material-induced activation events. J. Lab. Clin. Med. 125(2), 276-287 (1995).
76. Shimono, T, Shomura Y, Tani K et al. Clinical evaluation of a silicone coated hollow fiber oxygenator. ASAIO J. 43(5), M735-M739 (1997).
77. Shimamoto A, Kanemitsu S, Fujinaga K et al. Biocompatibility of silicone-coated oxygenator in cardiopulmonary bypass. Ann. Thorac. Surg. 69(1), 115-120 (2000).
78. Durrani AA, Hayward JA, Chapman D. Biomembranes as models for polymer surfaces. II. The syntheses of reactive species for covalent coupling of phosphorylcholine to polymer surfaces. Biomaterials 7(2), 121-125 (1986).
79. Sugiyama K, Matsumoto T, Yamazaki Y. Evaluation of biocompatibility of the surface of polyethylene films modified with various water soluble polymers using Ar plasma-post polymerization technique. Macromol. Mater. Eng. 282, 5-12 (2000).
80. Murphy EF, Lu JR, Brewer J, Russell J, Penfold J. The reduced adsorption of proteins at the phosphoryl choline incorporated polymer-water interface. Langmuir 15, 1313-1322 (1999).
81. Lewis AL, Tolhurst LA, Stratford PW. Analysis of a phosphorylcholine-based polymer coating on a coronary stent pre- and post-implantation. Biomaterials 23, 1697-1706 (2002).
82. Lewis AL, Furze JD, Small S et al. Long-term stability of a coronary stent coating post-implantation. J. Biomed. Mater. Res. 63(6), 699-705 (2002).
83. De Somer F, Francois K, van Oeveren W et al. Phosphorylcholine coating of extracorporeal circuits provides natural protection against blood activation by the material surface. Eur. J. Cardiothorac. Surg. 18(5), 602-606 (2000).
84. de Haan J, Boonstra PW, Monnink SHJ, Ebels T, van Oeveren W. Retransfusion of suctioned blood during cardiopulmonary bypass impairs hemostasis. Ann. Thorac. Surg. 59, 901-907 (1995).
85. Chung JH, Gikakis N, Rao K, Drake TA, Colman RW, Edmunds LH. Pericardial blood activates the extrinsic coagulation pathway during clinical cardiopulmonary bypass. Circulation 93, 2014-2018 (1996).
86. De Somer F, Van Belleghem Y, Caes F et al. Tissue factor as the main activator of the coagulation system during cardiopulmonary bypass. J. Thorac. Cardiovasc. Surg. 123(5), 951-958 (2002).
87. Tabuchi N, de Haan J, Boonstra PW, van Oeveren W. Activation of fibrinolysis in the pericardial cavity during cardiopulmonary bypass. J. Thorac. Cardiovasc. Surg. 106, 828-833 (1993).
88. Weitz JI, Hudoba M, Massel D, Maraganore J, Hirsh J. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III- independent inhibitors. J. Clin. Invest. 86, 385-391 (1990).
89. Ernofsson M, Thelin S, Siegbahn A. Monocyte tissue factor expression, cell activation, and thrombin formation during cardiopulmonary bypass: a clinical study. J. Thorac. Cardiovasc. Surg. 113, 576-584 (1997).
90. Parratt R, Hunt BJ. Direct activation of factor X by monocytes occurs during cardiopulmonary bypass. Br. J. Haematol. 101, 40-46 (1998).
91. Hattori T, Khan MM, Colman RW, Edmunds LH Jr. Plasma tissue factor plus activated peripheral mononuclear cells activate factors VII and X in cardiac surgical wounds. J. Am. Coll. Cardiol. 46(4), 707-713 (2005).
92. Nollert G, Schwabenland I, Maktav D et al. Miniaturized cardiopulmonary bypass in coronary artery bypass surgery: marginal impact on inflammation and coagulation but loss of safety margins. Ann. Thorac. Surg. 80(6), 2326-2332 (2005).
93. Mack MJ, Brown PP, Kugelmass AD et al. Current status and outcomes of coronary revascularization 1999 to 2002: 148,396 surgical and percutaneous procedures. Ann. Thorac. Surg. 77(3), 761-766 (2004).